Bayer’s Hyrnuo gets US FDA accelerated approval to treat patients with previously treated advanced HER2-mutant NSCLC
Following Priority Review and Breakthrough Therapy Designation, the US Food and Drug Administration (FDA) has granted accelerated approval for Hyrnuo (sevabertinib), for the treatment of adult patients with locally advanced or metastatic non-squamous non- …